Article citationsMore>>
Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Parkhomenko, A., Tavazzi, L., Levesque, V., Mori, C., Roubert, B., Filippatos, G., Ruschitzka, F. and Anker, S.D. (2015) Beneficial Effects of Long-Term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency. European Heart Journal, 36, 657-668.
https://doi.org/10.1093/eurheartj/ehu385
has been cited by the following article:
-
TITLE:
Iron Succinate Increased Ferritin and Transferrin Saturation in Non-Anaemic Patients with Heart Failure and Iron Deficiency—A Pilot Study
AUTHORS:
Kurt Boman, Mona Olofsson
KEYWORDS:
Iron Deficiency, Non-Anemic, Heart Failure, Iron Succinate
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.11 No.1,
January
13,
2021
ABSTRACT:
Introduction: Iron deficiency (ID) is often present (32% - 65%) in patients with heart failure (HF). Oral iron absorption in patients with HF is generallypoor. This is the reason why oral treatment is not recommended. Aim: To test whether oral iron succinate significantly increases iron deposits in non-anaaemic patients with HF. Methods: ID was defined as ferritin 2+ plus 100 mg succinate) in the morning and one tablet at bedtime for at least 3 months. Hemoglobin, CRP, ferritin, iron, TSAT, and hepcidin were analyzed before starting treatment, at 6 weeks, and at 3 months end of study (EOS). Results: Five women and 15 men were included in the study. The level of ferritin increased significantly from baseline to 6 weeks (47 to 78 μg/L, p = 0.009) and baseline to EOS (47 to 85 μg/L, p = 0.001). TSAT increased significantly from baseline to 6 weeks (20% to 27%, p = 0.046) and baseline to EOS (20% to 25%, p = 0.043). Hepcidin increased significantly from baseline to 6 weeks (2.5 nmol/L to 4.8 nmol/L, p = 0.006) and baseline to EOS (2.5 to 4.2 nmol/L, p = 0.02). Conclusion: Oral iron succinate significantly increased iron uptake, almost doubling the ferritin levels and increasing the TSAT, in patients with HF. Our findings challenge the opinion that oral iron treatment cannot significantly increase iron deposits in non-anemic patients with ID and HF.
Related Articles:
-
Maria Rosaria De Pascale, Maria Beatrice Rondinelli, Flora Ascione, Vincenzo Maffei, Chiara Di Lorenzo, Sarah Scagliarini, Raffaella Faraonio, Antonio Faiella
-
Shancy Shabu, Rasika Jayasekara
-
Yubo Xu, Zehua Xu, Huiwen Li, Zhilin Sun, Yuewei Li
-
Dakaboué Germain Mandi, Dangwé Temoua Naïbé, Joel Bamouni, Rélwendé Aristide Yaméogo, Yibar Kambiré, Koudougou Jonas Kologo, Georges Rosario Christian Millogo, Nobila Valentin Yaméogo, Anna Thiam Tall, Patrice Zabsonré
-
Assétou Soukho Kaya, Abdel Kader Traoré, Djibril Sy, Djenebou Traoré, Ilo Diall, Youssouf Fofana, Ibahima Amadou Dembélé, Boua Daoud Camara, Mamadou Saliou, Karim Dao, Mamadou Cissoko, Kaly Kéïta, Barry Boubacar Sangaré, Mamadou Mallé, Alassane A. Doumbia, Hadiza A. Kaïlou, Mamadou Dembélé, Hamar Alassane Traoré